Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$3.11 USD
+0.05 (1.63%)
Updated May 24, 2024 04:00 PM ET
After-Market: $3.10 -0.01 (-0.32%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
CLRB 3.11 +0.05(1.63%)
Will CLRB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CLRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLRB
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
CLRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLRB
Cellectar Biosciences files for $300M mixed securities shelf
Cellectar Biosciences files $300M mixed securities shelf
Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis
Cellectar Biosciences: Still Working On That Hit (Maintain Buy)
Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline